Lynn Kirkpatrick

2.0k citations

23 papers · 1.6k indexed · h-index 15

Impact in

Cancer Research top 2%
- Cancer, Hypoxia, and Metabolism
Molecular Biology top 10%
- PI3K/AKT/mTOR signaling in cancer
- ATP Synthase and ATPases Research
- RNA modifications and cancer
- Redox biology and oxidative stress

Papers in ⓘ

Oncology 9
- Cancer-related Molecular Pathways 3
Cancer Research 4
- Cancer, Hypoxia, and Metabolism 4

Co-authors: Garth Powis (15 shared papers)Ryan Williams (7 shared papers)Gillian Paine-Murrieta (3 shared papers)Sarah J. Welsh (2 shared papers)Nathan T. Ihle (5 shared papers)Robert J. Halter (3 shared papers)Amanda F. Baker (4 shared papers)Peter Wipf (3 shared papers)
Journals: Molecular Cancer Therapeutics (6 papers)Cancer Chemotherapy and Pharmacology (2 papers)Cancer Research (2 papers)Neoplasia (1 paper)Investigational New Drugs (1 paper)
Partner nations: United States South Korea Belgium

In The Last Decade

Lynn Kirkpatrick

22 papers receiving 1.6k citations

Peers

Countries citing papers authored by Lynn Kirkpatrick

Since Specialization

Citations

This map shows the geographic impact of Lynn Kirkpatrick's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Lynn Kirkpatrick with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Lynn Kirkpatrick more than expected).

Fields of papers citing papers by Lynn Kirkpatrick

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Lynn Kirkpatrick. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Lynn Kirkpatrick. The network helps show where Lynn Kirkpatrick may publish in the future.

Co-authors

The 25 scholars most cited alongside Lynn Kirkpatrick, linked wherever they have co-authored with each other. Click a name or a connecting line to browse the papers they share.

Border = papers with Lynn Kirkpatrick Line = papers co-authored together Lynn Kirkpatrick links everyone, so they are left out of the graph.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

Showing the 20 most-cited of 23 papers — load more, or switch the sort, to bring in the rest.

#	Work
1	Hypoxia inducible factor-1α as a cancer drug target Molecular Cancer Therapeutics ·Garth Powis, Lynn Kirkpatrick	2004	264
2	Molecular pharmacology and antitumor activity of PX-866, a novel inhibitor of phosphoinositide-3-kinase signaling Molecular Cancer Therapeutics ·Nathan T. Ihle, Ryan Williams, Sherry Chow, Wade M. Chew, Margareta Berggren, Gillian Paine-Murrieta, Daniel J. Minion, Robert J. Halter, Peter Wipf, Robert T. Abraham, Lynn Kirkpatrick, Garth Powis	2004	264
3	Antitumor activity and pharmacodynamic properties of PX-478, an inhibitor of hypoxia-inducible factor-1alpha. PubMed ·Sarah J. Welsh, Ryan Williams, Lynn Kirkpatrick, Gillian Paine-Murrieta, Garth Powis	2004	243
4	Antitumor activity and pharmacodynamic properties of PX-478, an inhibitor of hypoxia-inducible factor-1α Molecular Cancer Therapeutics ·Sarah J. Welsh, Ryan Williams, Lynn Kirkpatrick, Gillian Paine-Murrieta, Garth Powis	2004	192
5	Dynamic Contrast-Enhanced and Diffusion MRI Show Rapid and Dramatic Changes in Tumor Microenvironment in Response to Inhibition of HIF-1α Using PX-478 Neoplasia ·Bénédicte F. Jordan, Matthew Runquist, Natarajan Raghunand, Amanda F. Baker, Ryan Williams, Lynn Kirkpatrick, Garth Powis, Robert J. Gillies	2005	107
6	A randomized phase II study of PX-12, an inhibitor of thioredoxin in patients with advanced cancer of the pancreas following progression after a gemcitabine-containing combination Cancer Chemotherapy and Pharmacology ·Ramesh K. Ramanathan, James L. Abbruzzese, Tomislav Dragovich, Lynn Kirkpatrick, Jose Guillen, Amanda F. Baker, Linda Pestano, Sylvan Green, Daniel D. Von Hoff	2010	104
7	Uveal Melanoma UK National Guidelines European Journal of Cancer ·Paul Nathan, Victoria M.L. Cohen, Sarah E. Coupland, K. Curtis, Bertil Damato, J. Evans, S. Fenwick, Lynn Kirkpatrick, O. Li, E. Marshall, K. McGuirk, Christian H. Ottensmeier, Neil Pearce, Sachin M. Salvi, Brian Stedman, Peter W. Szlosarek, Niruwan Turnbull	2015	89
8	Synthesis and biological evaluation of synthetic viridins derived from C(20)-heteroalkylation of the steroidal PI-3-kinase inhibitor wortmannin Organic & Biomolecular Chemistry ·Peter Wipf, Daniel J. Minion, Robert J. Halter, Margareta Berggren, Caroline B. Ho, Gary G. Chiang, Lynn Kirkpatrick, Robert T. Abraham, Garth Powis	2004	69
9	Treatment with HIF-1α Antagonist PX-478 Inhibits Progression and Spread of Orthotopic Human Small Cell Lung Cancer and Lung Adenocarcinoma in Mice Journal of Thoracic Oncology ·Jörg J. Jacoby, Baruch Erez, Maria Korshunova, Ryan Williams, Kazuhisa Furutani, Osamu Takahashi, Lynn Kirkpatrick, Scott M. Lippman, Garth Powis, Michael S. O’Reilly, Roy S. Herbst	2010	67
10	In Vivo Molecular Pharmacology and Antitumor Activity of the Targeted Akt Inhibitor PX-316 Oncology Research Featuring Preclinical and Clinical Cancer Therapeutics ·Emmanuelle J. Meuillet, Nathan T. Ihle, Amanda F. Baker, Jaime M.C. Gard, Chelsea Stamper, Ryan Williams, Amy Coon, Daruka Mahadevan, Benjamin L. George, Lynn Kirkpatrick, Garth Powis	2004	46
11	A phase I trial of PX-12, a small-molecule inhibitor of thioredoxin-1, administered as a 72-hour infusion every 21 days in patients with advanced cancers refractory to standard therapy Investigational New Drugs ·Ramesh K. Ramanathan, Joe Stephenson, Glen J. Weiss, Linda Pestano, Ann M. Lowe, Alton Hiscox, Rafael A. Leos, Julie Martin, Lynn Kirkpatrick, Donald Richards	2011	32
12	The skin and hair as surrogate tissues for measuring the target effect of inhibitors of phosphoinositide-3-kinase signaling Cancer Chemotherapy and Pharmacology ·Ryan Williams, Amanda F. Baker, Nathan T. Ihle, Ashley R. Winkler, Lynn Kirkpatrick, Garth Powis	2006	25
13	Pleckstrin Homology [PH] domain, structure, mechanism, and contribution to human disease Biomedicine & Pharmacotherapy ·Garth Powis, Emmanuelle J. Meuillet, Martín Indarte, Garrett Booher, Lynn Kirkpatrick	2023	24
14	Peroxisome proliferator-activated receptor γ agonist pioglitazone prevents the hyperglycemia caused by phosphatidylinositol 3-kinase pathway inhibition by PX-866 without affecting antitumor activity Molecular Cancer Therapeutics ·Nathan T. Ihle, Robert Lemos, David A. Schwartz, Junghwan Oh, Robert J. Halter, Peter Wipf, Lynn Kirkpatrick, Garth Powis	2009	24
15	An Inhibitor of the Pleckstrin Homology Domain of CNK1 Selectively Blocks the Growth of Mutant KRAS Cells and Tumors Cancer Research ·Martín Indarte, Roisin Puentes, Marco Maruggi, Nathan T. Ihle, Geoffrey Grandjean, Michael J. Scott, Zamal Ahmed, Emmanuelle J. Meuillet, Shuxing Zhang, Robert Lemos, Lei Du‐Cuny, Fabiana Izidro Layng, Ricardo G. Correa, Laurie A. Bankston, Robert Liddington, Lynn Kirkpatrick, Garth Powis	2019	23
16	Relationship among measures of evaluation ability (problem solving), creative thinking, and intelligence Contemporary Educational Psychology ·John C. Houtz, Catherine Montgomery, Lynn Kirkpatrick, John F. Feldhusen	1979	9
17	Results from phase Ib studies of PX-12, a thioredoxin inhibitor in patients with advanced solid malignancies Journal of Clinical Oncology ·Rajesh Ramanathan, Tomislav Dragovich, Donald Richards, J. Stephenson, Linda Pestano, Alton Hiscox, Rafael A. Leos, Shein Chung Chow, John Millard, Lynn Kirkpatrick	2009	5
18	PLEKHA7 signaling is necessary for the growth of mutant KRAS driven colorectal cancer Experimental Cell Research ·Hei‐Cheul Jeung, Roisin Puentes, Alexander E. Aleshin, Martín Indarte, Ricardo G. Correa, Laurie A. Bankston, Fabiana Izidro Layng, Zamal Ahmed, Ignacio I. Wistuba, Yuanyuan Yao, Daniela G. Duenas, Shuxing Zhang, Emmanuelle J. Meuillet, Francesca M. Marassi, Robert Liddington, Lynn Kirkpatrick, Garth Powis	2021	4
19	Incubators for innovators Nature Biotechnology ·Lynn Kirkpatrick	2015	4
20	Abstract A199: The plekstrin-homology-domain-containing protein PLEKHA7 is a novel target for selectively inhibiting mutant KRAS colon cancer cell proliferation. Molecular Cancer Therapeutics ·Hei-Cheul Jeung, Galina M. Kiriakova, Lynn Kirkpatrick, Martín Indarte, Garth Powis	2011	2

About Lynn Kirkpatrick

Lynn Kirkpatrick is a scholar working on Oncology, Cancer Research, Molecular Biology, Genetics and Anesthesiology and Pain Medicine, having authored 23 papers that have together received 1.6k indexed citations. Recurring topics across this work include PI3K/AKT/mTOR signaling in cancer (7 papers), Cancer, Hypoxia, and Metabolism (4 papers), ATP Synthase and ATPases Research (3 papers), Cancer-related Molecular Pathways (3 papers), Synthesis and biological activity (2 papers), Chronic Lymphocytic Leukemia Research (2 papers), Metabolism, Diabetes, and Cancer (2 papers) and Biochemical and Molecular Research (2 papers). The work is most often cited by research in Cancer Research (679 citations), Molecular Biology (991 citations), Oncology (295 citations), Biotechnology (91 citations) and Ophthalmology (95 citations). Lynn Kirkpatrick has collaborated with scholars based in United States, South Korea and Belgium. Frequent co-authors include Garth Powis, Ryan Williams, Gillian Paine-Murrieta, Sarah J. Welsh, Nathan T. Ihle, Robert J. Halter, Amanda F. Baker, Peter Wipf, Robert T. Abraham and Margareta Berggren. Their work appears in journals such as Molecular Cancer Therapeutics, Cancer Chemotherapy and Pharmacology, Cancer Research, Neoplasia and Investigational New Drugs.

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact